Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients

Tang, Shicong; Zheng, Kai; Tang, Yiyin; Li, Zhen; Zou, Tianning; Liu, Dequan

doi:10.1007/s12038-019-9861-y

Cited by 61 publications

(68 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the detection of TRPC5-positive exosomes can be used to monitor chemotherapy resistance in real time. Another group found that the level of serum exosomal lncRNA HOTAIR from BC patients was significantly higher than that in healthy individuals 114 . Importantly, the level of exosomal lncRNA HOTAIR significantly decreased in all patients 3 months after the operation, suggesting that the source of serum HOTAIR is from the tumor tissue, and its level is related to tumor burden and disease invasiveness.…”

Section: Potential Clinical Applications Of Exosomes In Bc Drug Resismentioning

confidence: 99%

“…Importantly, the level of exosomal lncRNA HOTAIR significantly decreased in all patients 3 months after the operation, suggesting that the source of serum HOTAIR is from the tumor tissue, and its level is related to tumor burden and disease invasiveness. Also, a high expression level of serum exosomal HOTAIR was associated with a poorer response to neoadjuvant chemotherapy and TAM therapy 114 . Stevic et al 115 showed that some miRNAs were selectively enriched in exosomes of HER2 + BC and TNBC and were also related with the clinicopathological parameters and pathological complete response within the BC subtypes.…”

Section: Potential Clinical Applications Of Exosomes In Bc Drug Resismentioning

confidence: 99%

See 1 more Smart Citation

Exosomes and breast cancer drug resistance

et al. 2020

View full text Add to dashboard Cite

Drug resistance is a daunting challenge in the treatment of breast cancer (BC). Exosomes, as intercellular communicative vectors in the tumor microenvironment, play an important role in BC progression. With the in-depth understanding of tumor heterogeneity, an emerging role of exosomes in drug resistance has attracted extensive attention. The functional proteins or non-coding RNAs contained in exosomes secreted from tumor and stromal cells mediate drug resistance by regulating drug efflux and metabolism, pro-survival signaling, epithelial–mesenchymal transition, stem-like property, and tumor microenvironmental remodeling. In this review, we summarize the underlying associations between exosomes and drug resistance of BC and discuss the unique biogenesis of exosomes, the change of exosome cargo, and the pattern of release by BC cells in response to drug treatment. Moreover, we propose exosome as a candidate biomarker in predicting and monitoring the therapeutic drug response of BC and as a potential target or carrier to reverse the drug resistance of BC.

show abstract

Section: Potential Clinical Applications Of Exosomes In Bc Drug Resismentioning

confidence: 99%

Section: Potential Clinical Applications Of Exosomes In Bc Drug Resismentioning

confidence: 99%

Exosomes and breast cancer drug resistance

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Genetic polymorphisms of HOTAIR are associated with BC risk in different races [119,120,121]. The latest findings suggest that HOTAIR-containing exosomes could be detected in BC patients’ blood [122,123]. Moreover, serum exosomal HOTAIR levels are higher in BC patients than in healthy subjects [122].…”

Section: Lncrnas In Breast Cancer (Bc)mentioning

confidence: 99%

Long Non-Coding RNA in the Pathogenesis of Cancers

Chi

Wang

et al. 2019

Cells

629

452

View full text Add to dashboard Cite

The incidence and mortality rate of cancer has been quickly increasing in the past decades. At present, cancer has become the leading cause of death worldwide. Most of the cancers cannot be effectively diagnosed at the early stage. Although there are multiple therapeutic treatments, including surgery, radiotherapy, chemotherapy, and targeted drugs, their effectiveness is still limited. The overall survival rate of malignant cancers is still low. It is necessary to further study the mechanisms for malignant cancers, and explore new biomarkers and targets that are more sensitive and effective for early diagnosis, treatment, and prognosis of cancers than traditional biomarkers and methods. Long non-coding RNAs (lncRNAs) are a class of RNA transcripts with a length greater than 200 nucleotides. Generally, lncRNAs are not capable of encoding proteins or peptides. LncRNAs exert diverse biological functions by regulating gene expressions and functions at transcriptional, translational, and post-translational levels. In the past decade, it has been demonstrated that the dysregulated lncRNA profile is widely involved in the pathogenesis of many diseases, including cancer, metabolic disorders, and cardiovascular diseases. In particular, lncRNAs have been revealed to play an important role in tumor growth and metastasis. Many lncRNAs have been shown to be potential biomarkers and targets for the diagnosis and treatment of cancers. This review aims to briefly discuss the latest findings regarding the roles and mechanisms of some important lncRNAs in the pathogenesis of certain malignant cancers, including lung, breast, liver, and colorectal cancers, as well as hematological malignancies and neuroblastoma.

show abstract

“…In HR+ breast cancer, elevated circulating exosomal levels of mRNAs encoding cell cycle-regulated thymidine kinase 1 (TK1) and cyclin-dependent kinase 9 (CDK9) were associated with poor clinical response to the CDK4/CDK6 inhibitor palbociclib [ 115 ]. Recently, it was reported that higher levels of the lncRNA HOTAIR were found in circulating exosomes in breast cancer patients than in healthy individuals [ 116 ]. Exosomal HOTAIR levels were also associated with poor prognosis, and it was suggested as a possible predictor of response to chemotherapy and tamoxifen treatment.…”

Section: Liquid Biopsies On Breast Cancermentioning

confidence: 99%

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies

Gabriel

Knutsen

Perander

2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women worldwide. Although the five-, ten- and fifteen-year survival rates are good for breast cancer patients diagnosed with early-stage disease, some cancers recur many years after completion of primary therapy. Tumor heterogeneity and clonal evolution may lead to distant metastasis and therapy resistance, which are the main causes of breast cancer-associated deaths. In the clinic today, imaging techniques like mammography and tissue biopsies are used to diagnose breast cancer. Even though these methods are important in primary diagnosis, they have limitations when it comes to longitudinal monitoring of residual disease after treatment, disease progression, therapy responses, and disease recurrence. Over the last few years, there has been an increasing interest in the diagnostic, prognostic, and predictive potential of circulating cancer-derived material acquired through liquid biopsies in breast cancer. Thanks to the development of sensitive devices and platforms, a variety of tumor-derived material, including circulating cancer cells (CTCs), circulating DNA (ctDNA), and biomolecules encapsulated in extracellular vesicles, can now be extracted and analyzed from body fluids. Here we will review the most recent studies on breast cancer, demonstrating the clinical potential and utility of CTCs and ctDNA. We will also review literature illustrating the potential of circulating exosomal RNA and proteins as future biomarkers in breast cancer. Finally, we will discuss some of the advantages and limitations of liquid biopsies and the future perspectives of this field in breast cancer management.

show abstract

Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients

Cited by 61 publications

References 41 publications

Exosomes and breast cancer drug resistance

Exosomes and breast cancer drug resistance

Long Non-Coding RNA in the Pathogenesis of Cancers

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies

Contact Info

Product

Resources

About